ReCode Therapeutics

About ReCode Therapeutics

ReCode Therapeutics is focused on powering the future of genetic medicines through superior delivery systems. They develop therapeutics for genetically defined diseases with no existing treatment options, such as cystic fibrosis and primary ciliary dyskinesia, aiming to transcend limitations of current genetic medicine delivery systems.

Products & Services

SORT LNP Platform:A first-in-class modular technology for targeted delivery of genetic medicines to organs, tissues, and cells beyond the liver, engineered for optimal administration modes.

Precision Genetic Medicines:A pipeline of rare disease therapeutics using optimized mRNA and gene correction with redosing capability.

Versatile Cargo & Delivery Potential:A platform enabling the packaging and delivery of a wide range of genetic medicines via multiple administration routes.

Specialties

Targeted Delivery Technology Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) Platform Precision Genetic Medicines for Rare Diseases Cystic Fibrosis Therapeutics Primary Ciliary Dyskinesia Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Additional Financing T: - FT: Additional Financing	A: 29000000 MR: - FA: over $29 million FAN: 29000000	D: 2025-09-29 FD: 2025-09-29	1 investors
2	RT: Grant T: - FT: Grant	A: 15000000 MR: - FA: up to $15 million FAN: 15000000	D: 2024-11-18 FD: 2024-11-18	1 investors
3	RT: Investment T: - FT: Investment	A: 15000000 MR: - FA: up to $15 million FAN: 15000000	D: 2024-11-18 FD: 2024-11-18	1 investors
4	RT: Series B T: - FT: Series B	A: 260000000 MR: - FA: $260 million FAN: 260000000	D: 2023-09-19 FD: 2023-09-19	12 investors
5	RT: Equity Investment T: - FT: Equity Investment	A: 15000000 MR: - FA: up to $15 million FAN: 15000000	D: 2023-01-10 FD: 2023-01-10	1 investors
6	RT: Strategic Investment T: - FT: Strategic Investment	A: 15000000 MR: - FA: up to $15 million FAN: 15000000	D: 2023-01-10 FD: 2023-01-10	1 investors

Additional Financing Latest

2025-09-29

$29.0M

1 investor (Pro only)

Grant 2024-11-18

$15.0M

Investment 2024-11-18

$15.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Daniel J. Siegwart

Chair of the SAB

S

Shehnaaz Suliman

President & Chief Executive Officer

J

John G. Matthews

Chief Medical Officer

J

Jessica Couch

Chief Scientific Officer

V

Vladimir Kharitonov

Senior Vice President, CMC and Pharmaceutical Sciences

M

Max Barker

General Counsel

View 18 more team members with Pro

Unlock Full Team Directory

Recent News